Literature DB >> 32535123

Splanchnic Nerve Block for Chronic Heart Failure.

Marat Fudim1, Richard L Boortz-Marx2, Arun Ganesh2, Adam D DeVore1, Chetan B Patel3, Joseph G Rogers1, Aubrie Coburn3, Inneke Johnson3, Amanda Paul3, Brian J Coyne3, Sunil V Rao1, J Antonio Gutierrez3, Todd L Kiefer3, David F Kong1, Cynthia L Green4, W Schuyler Jones1, G Michael Felker1, Adrian F Hernandez1, Manesh R Patel5.   

Abstract

OBJECTIVES: We hypothesized that splanchnic nerve blockade (SNB) would attenuate increased exercise-induced cardiac filling pressures in patients with chronic HF.
BACKGROUND: Chronic heart failure (HF) is characterized by limited exercise capacity driven in part by an excessive elevation of cardiac filling pressures.
METHODS: This is a prospective, open-label, single-arm interventional study in chronic HF patients. Eligible patients had a wedge pressure ≥15 mm Hg at rest or ≥25 mm Hg with exercise on baseline right heart catheterization. Patients underwent cardiopulmonary exercise testing with invasive hemodynamic assessment, followed by percutaneous SNB with ropivacaine.
RESULTS: Nineteen patients were enrolled, 15 of whom underwent SNB. The average age was 58 ± 13 years, 7 (47%) patients were women and 6 (40%) were black. Left ventricular ejection fraction was ≤35% in 14 (93%) patients. No procedural complications were encountered. SNB reduced mean pulmonary arterial pressure at peak exercise from 54.1 ± 14.4 (pre-SNB) to 45.8 ± 17.7 mm Hg (p < 0.001) (post-SNB). Similarly, SNB reduced exercise-induced wedge pressure from 34.8 ± 10.0 (pre-SNB) to 25.1 ± 10.7 mm Hg (p < 0.001) (post-SNB). The cardiac index changed with peak exercise from 3.4 ± 1.2 (pre-SNB) to 3.8 ± 1.1 l/min/m2 (p = 0.011) (post-SNB). After SNB, patients exercised for approximately the same duration at a greater workload (33 ± 24 W vs. 50 ± 30 W; p = 0.019) and peak oxygen consumption VO2 (9.1 ± 2.5 vs. 9.8 ± 2.7 ml/kg/min; p = 0.053).
CONCLUSIONS: SNB reduced resting and exercise-induced pulmonary arterial and wedge pressure with favorable effects on cardiac output and exercise capacity. Continued efforts to investigate short- and long-term effects of SNB in chronic HF are warranted. Clinical Trials Registration (Abdominal Nerve Blockade in Chronic Heart Failure; NCT03453151).
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  congestion; heart failure; splanchnic nerve block; sympathetic nervous system

Year:  2020        PMID: 32535123     DOI: 10.1016/j.jchf.2020.04.010

Source DB:  PubMed          Journal:  JACC Heart Fail        ISSN: 2213-1779            Impact factor:   12.035


  12 in total

Review 1.  Targeting Preload in Heart Failure: Splanchnic Nerve Blockade and Beyond.

Authors:  Marat Fudim; Muhammad Shahzeb Khan; Anousheh Awais Paracha; Kenji Sunagawa; Daniel Burkhoff
Journal:  Circ Heart Fail       Date:  2022-03-15       Impact factor: 8.790

Review 2.  Venous Tone and Stressed Blood Volume in Heart Failure: JACC Review Topic of the Week.

Authors:  Marat Fudim; David M Kaye; Barry A Borlaug; Sanjiv J Shah; Stuart Rich; Navin K Kapur; Maria Rosa Costanzo; Michael I Brener; Kenji Sunagawa; Daniel Burkhoff
Journal:  J Am Coll Cardiol       Date:  2022-05-10       Impact factor: 27.203

3.  The splanchnic reservoir: an oasis for blood volume in heart failure with preserved ejection fraction?

Authors:  Ravi B Patel; Sanjiv J Shah
Journal:  Eur J Heart Fail       Date:  2021-07-16       Impact factor: 17.349

Review 4.  Levosimendan-induced venodilation is mediated by opening of potassium channels.

Authors:  Daniel Burkhoff; Stuart Rich; Piero Pollesello; Zoltán Papp
Journal:  ESC Heart Fail       Date:  2021-10-30

5.  Early Hemodynamic Changes following Surgical Ablation of the Right Greater Splanchnic Nerve for the Treatment of Heart Failure with Preserved Ejection Fraction.

Authors:  Piotr Gajewski; Marat Fudim; Veraprapas Kittipibul; Zoar J Engelman; Jan Biegus; Robert Zymliński; Piotr Ponikowski
Journal:  J Clin Med       Date:  2022-02-18       Impact factor: 4.241

Review 6.  A Glimpse Into the Future of Transcatheter Interventional Heart Failure Therapies.

Authors:  Roberto C Cerrud-Rodriguez; Daniel Burkhoff; Azeem Latib; Juan F Granada
Journal:  JACC Basic Transl Sci       Date:  2021-11-24

7.  Splanchnic Nerve Ablation for Volume Management in Heart Failure.

Authors:  Marat Fudim; Zoar J Engelman; Vivek Y Reddy; Sanjiv J Shah
Journal:  JACC Basic Transl Sci       Date:  2022-04-04

Review 8.  Research Opportunities in Autonomic Neural Mechanisms of Cardiopulmonary Regulation: A Report From the National Heart, Lung, and Blood Institute and the National Institutes of Health Office of the Director Workshop.

Authors:  Reena Mehra; Olga A Tjurmina; Olujimi A Ajijola; Rishi Arora; Donald C Bolser; Mark W Chapleau; Peng-Sheng Chen; Colleen E Clancy; Brian P Delisle; Michael R Gold; Jeffrey J Goldberger; David S Goldstein; Beth A Habecker; M Louis Handoko; Robert Harvey; James P Hummel; Thomas Hund; Christian Meyer; Susan Redline; Crystal M Ripplinger; Marc A Simon; Virend K Somers; Stavros Stavrakis; Thomas Taylor-Clark; Bradley Joel Undem; Richard L Verrier; Irving H Zucker; George Sopko; Kalyanam Shivkumar
Journal:  JACC Basic Transl Sci       Date:  2022-01-26

Review 9.  Autonomic Testing Optimizes Therapy for Heart Failure and Related Cardiovascular Disorders.

Authors:  Nicholas L DePace; Joe Colombo; Kaushik Mandal; Howard J Eisen
Journal:  Curr Cardiol Rep       Date:  2022-09-05       Impact factor: 3.955

Review 10.  Extra-cardiac targets in the management of cardiometabolic disease: Device-based therapies.

Authors:  Ana Jorbenadze; Marat Fudim; Felix Mahfoud; Phillip B Adamson; Tarek Bekfani; Rolf Wachter; Horst Sievert; Piotr P Ponikowski; John G F Cleland; Stefan D Anker
Journal:  ESC Heart Fail       Date:  2021-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.